Integer (NYSE:ITGR) Price Target Raised to $145.00

Integer (NYSE:ITGR) had its target price increased by Citigroup from $130.00 to $145.00 in a research note published on Wednesday morning,Benzinga reports. The firm currently has a neutral rating on the medical equipment provider’s stock.

A number of other research analysts have also recently commented on the stock. Truist Financial increased their target price on shares of Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler reissued an “overweight” rating and issued a $140.00 price objective (up previously from $125.00) on shares of Integer in a research note on Friday, October 25th. Benchmark raised their target price on shares of Integer from $130.00 to $140.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Bank of America upped their price target on shares of Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. Finally, Wells Fargo & Company reissued an “overweight” rating and set a $160.00 price objective on shares of Integer in a report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Integer has an average rating of “Moderate Buy” and a consensus price target of $145.44.

Integer Stock Performance

Shares of Integer stock opened at $138.65 on Wednesday. The company has a 50 day moving average of $133.58 and a 200-day moving average of $125.61. The company has a market cap of $4.65 billion, a PE ratio of 42.79, a price-to-earnings-growth ratio of 2.02 and a beta of 1.12. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67. Integer has a 1-year low of $94.56 and a 1-year high of $142.76.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.07. Integer had a return on equity of 11.63% and a net margin of 6.70%. The company had revenue of $431.42 million for the quarter, compared to analyst estimates of $440.59 million. During the same quarter last year, the company posted $1.27 EPS. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, equities research analysts forecast that Integer will post 5.33 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Contravisory Investment Management Inc. raised its position in shares of Integer by 55.9% during the third quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 80 shares during the last quarter. Huntington National Bank raised its holdings in Integer by 8,933.3% during the 3rd quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 268 shares during the last quarter. Quest Partners LLC lifted its position in shares of Integer by 3,688.9% in the 2nd quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 332 shares during the period. GAMMA Investing LLC boosted its stake in shares of Integer by 74.1% in the 3rd quarter. GAMMA Investing LLC now owns 653 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 278 shares during the last quarter. Finally, Innealta Capital LLC acquired a new stake in shares of Integer during the second quarter worth $110,000. 99.29% of the stock is owned by institutional investors and hedge funds.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.